Skip to main content
SpringerLink
Log in

Neuropeptide Y1 receptor inhibits cell growth through inactivating mitogen-activated protein kinase signal pathway in human hepatocellular carcinoma

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers, and its incidence is increasing worldwide. Neuropeptide Y (NPY) broadly expressed in the central and peripheral nervous system. It participates in multiple physiological and pathological processes through specific receptors. Evidences are accumulating that NPY is involved in development and progression in neuro- or endocrine-related cancers. However, little is known about the potential roles and underlying mechanisms of NPY receptors in HCC. In this study, we analyzed the expression of NPY receptors by real-time polymerase chain reaction, Western blot, and immunohistochemical staining. Correlation between NPY1R levels and clinicopathological characteristics, and survival of HCC patients were explored, respectively. Cell proliferation was researched by CCK-8 in vitro, and tumor growth was studied by nude mice xenografts in vivo. We found that mRNA and protein level of NPY receptor Y1 subtype (NPY1R) significantly decreased in HCC tissues. Low expression of NPY1R closely correlated with poor prognosis in HCC patients. Proliferation of HCC cells was significantly inhibited by recombinant NPY protein in vitro. This inhibitory effect could be blocked by selected NPY1R antagonist BIBP3226. Furthermore, overexpression of NPY1R could significantly inhibit HCC cell proliferation. Knockdown of NPY1R promoted cell multiplication in vitro and increased tumorigenicity and tumor growth in vivo. NPY1R was found to participate in the inhibition of cell proliferation via inactivating mitogen-activated protein kinase signal pathway in HCC cells. Collectively, NPY1R plays an inhibitory role in tumor growth and may be a promising therapeutic target for HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

Abbreviations

HCC:

Hepatocellular carcinoma

NPY:

Neuropeptide Y

PPY:

Pancreatic polypeptide

PYY:

Peptide YY

NPY1R:

Neuropeptide Y receptor Y1 subtype

NPY2R:

Neuropeptide Y receptor Y2 subtype

NPY5R:

Neuropeptide Y receptor Y5 subtype

MAPK:

Mitogen-activated protein kinase

ERK:

Extracellular signal-regulated kinase

JNK:

C-Jun N-terminal kinase

TNM stage:

Tumor-node-metastasis stage

References

  1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–27. doi:10.1056/NEJMra1001683.

    Article  CAS  PubMed  Google Scholar 

  2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.

    Article  PubMed  Google Scholar 

  3. Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol. 2014;109(4):542–53. doi:10.1038/ajg.2014.11.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164–71. doi:10.1053/jhep.2002.33156.

    Article  CAS  PubMed  Google Scholar 

  5. Fan ST, Mau Lo C, Poon RT, Yeung C, Leung Liu C, Yuen WK, et al. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg. 2011;253(4):745–58. doi:10.1097/SLA.0b013e3182111195.

    Article  PubMed  Google Scholar 

  6. Wan D, Gong Y, Qin W, Zhang P, Li J, Wei L, et al. Large-scale cDNA transfection screening for genes related to cancer development and progression. Proc Natl Acad Sci USA. 2004;101(44):15724–9. doi:10.1073/pnas.0404089101.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Soll C, Jang JH, Riener MO, Moritz W, Wild PJ, Graf R, et al. Serotonin promotes tumor growth in human hepatocellular cancer. Hepatology. 2010;51(4):1244–54. doi:10.1002/hep.23441.

    Article  CAS  PubMed  Google Scholar 

  8. Zhao Y, Wang X, Wang T, Hu X, Hui X, Yan M, et al. Acetylcholinesterase, a key prognostic predictor for hepatocellular carcinoma, suppresses cell growth and induces chemosensitization. Hepatology. 2011;53(2):493–503. doi:10.1002/hep.24079.

    Article  CAS  PubMed  Google Scholar 

  9. Zhang M, Gong Y, Assy N, Minuk GY. Increased GABAergic activity inhibits alpha-fetoprotein mRNA expression and the proliferative activity of the HepG2 human hepatocellular carcinoma cell line. J Hepatol. 2000;32(1):85–91.

    Article  CAS  PubMed  Google Scholar 

  10. Li L, Hanahan D. Hijacking the neuronal NMDAR signaling circuit to promote tumor growth and invasion. Cell. 2013;153(1):86–100. doi:10.1016/j.cell.2013.02.051.

    Article  CAS  PubMed  Google Scholar 

  11. Tatemoto K, Carlquist M, Mutt V. Neuropeptide Y—a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature. 1982;296(5858):659–60.

    Article  CAS  PubMed  Google Scholar 

  12. Hirsch D, Zukowska Z. NPY and stress 30 years later: the peripheral view. Cell Mol Neurobiol. 2012;32(5):645–59. doi:10.1007/s10571-011-9793-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, Rone J, Movafagh S, Ji H, et al. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res. 1998;83(2):187–95.

    Article  CAS  PubMed  Google Scholar 

  14. Wraith A, Tornsten A, Chardon P, Harbitz I, Chowdhary BP, Andersson L, et al. Evolution of the neuropeptide Y receptor family: gene and chromosome duplications deduced from the cloning and mapping of the five receptor subtype genes in pig. Genome Res. 2000;10(3):302–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Kitlinska J, Abe K, Kuo L, Pons J, Yu M, Li L, et al. Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. Cancer Res. 2005;65(5):1719–28. doi:10.1158/0008-5472.CAN-04-2192.

    Article  CAS  PubMed  Google Scholar 

  16. Ruscica M, Dozio E, Boghossian S, Bovo G, Martos Riano V, Motta M, et al. Activation of the Y1 receptor by neuropeptide Y regulates the growth of prostate cancer cells. Endocrinology. 2006;147(3):1466–73. doi:10.1210/en.2005-0925.

    Article  CAS  PubMed  Google Scholar 

  17. Reubi JC, Gugger M, Waser B, Schaer JC. Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res. 2001;61(11):4636–41.

    CAS  PubMed  Google Scholar 

  18. Korner M, Waser B, Reubi JC. High expression of neuropeptide Y1 receptors in ewing sarcoma tumors. Clin Cancer Res. 2008;14(16):5043–9. doi:10.1158/1078-0432.CCR-07-4551.

    Article  PubMed  Google Scholar 

  19. Lu C, Everhart L, Tilan J, Kuo L, Sun CCJ, Munivenkatappa RB, et al. Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy. Oncogene. 2010;29(41):5630–42. doi:10.1038/onc.2010.301.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Ruscica M, Dozio E, Motta M, Magni P. Role of neuropeptide Y and its receptors in the progression of endocrine-related cancer. Peptides. 2007;28(2):426–34. doi:10.1016/j.peptides.2006.08.045.

    Article  CAS  PubMed  Google Scholar 

  21. Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, et al. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med. 2012;18(7):1052–9. doi:10.1038/nm.2795.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma. N Engl J Med. 1991;324(1):1–8. doi:10.1056/NEJM199101033240101.

    Article  CAS  PubMed  Google Scholar 

  23. Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, et al. Gene expression patterns in human liver cancers. Mol Biol Cell. 2002;13(6):1929–39. doi:10.1091/mbc.02-02-0023.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 2010;70(24):10202–12. doi:10.1158/0008-5472.CAN-10-2607.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology. 2007;45(4):938–47. doi:10.1002/hep.21622.

    Article  CAS  PubMed  Google Scholar 

  26. Mas VR, Maluf DG, Archer KJ, Yanek K, Kong X, Kulik L, et al. Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma. Mol Med. 2009;15(3–4):85–94. doi:10.2119/molmed.2008.00110.

    CAS  PubMed  Google Scholar 

  27. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9(2):166–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Xu WH, Zhang JB, Dang Z, Li X, Zhou T, Liu J, et al. Long non-coding RNA URHC regulates cell proliferation and apoptosis via ZAK through the ERK/MAPK signaling pathway in hepatocellular carcinoma. Int J Biol Sci. 2014;10(7):664–76. doi:10.7150/ijbs.8232.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Marcq I, Nyga R, Cartier F, Amrathlal RS, Ossart C, Ouled-Haddou H, et al. Identification of SLAMF3 (CD229) as an inhibitor of hepatocellular carcinoma cell proliferation and tumour progression. PLoS ONE. 2013;8(12):e82918. doi:10.1371/journal.pone.0082918.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Pongor E, Ledo N, Altdorfer K, Lengyel G, Feher E. Distribution and possible origin of neuropeptide-containing nerve elements in the mammalian liver. Acta Vet Hung. 2010;58(2):177–87. doi:10.1556/AVet.58.2010.2.4.

    Article  PubMed  Google Scholar 

  31. Medeiros PJ, Al-Khazraji BK, Novielli NM, Postovit LM, Chambers AF, Jackson DN. Neuropeptide Y stimulates proliferation and migration in the 4T1 breast cancer cell line. Int J Cancer. 2012;131(2):276–86. doi:10.1002/ijc.26350.

    Article  CAS  PubMed  Google Scholar 

  32. Min L, He B, Hui L. Mitogen-activated protein kinases in hepatocellular carcinoma development. Semin Cancer Biol. 2011;21(1):10–20. doi:10.1016/j.semcancer.2010.10.011.

    Article  CAS  PubMed  Google Scholar 

  33. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9(8):537–49. doi:10.1038/nrc2694.

    Article  CAS  PubMed  Google Scholar 

  34. Mitsui H, Takuwa N, Maruyama T, Maekawa H, Hirayama M, Sawatari T, et al. The MEK1-ERK map kinase pathway and the PI 3-kinase-Akt pathway independently mediate anti-apoptotic signals in HepG2 liver cancer cells. Int J Cancer. 2001;92(1):55–62.

    Article  CAS  PubMed  Google Scholar 

  35. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV. The role of cAMP-MAPK signalling in the regulation of human hepatocellular carcinoma growth in vitro. Eur J Gastroenterol Hepatol. 1999;11(12):1393–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was funded by the National Natural Science Foundation of China (Nos. 81502100, 81402024), China Postdoctoral Science Foundation (2016M591896), Jiangsu government scholarship for overseas studies, the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), and the Natural Science Foundation of Jiangsu Province, China (BK20140437).

Author information

Authors and Affiliations

  1. Basic Medical Research Centre in Medical College of Nantong University, Nantong, China

    Xiufang Lv, Fengbo Zhao, Baoying Hu, Xiu Gong, Juan Yang & Wenxin Qin

  2. Department of General Surgery, The Affiliated Hospital, Nantong University, Nantong, China

    Weidong Tang

  3. State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, No. 25/2200, Xietu Road, Shanghai, 200032, China

    Xisong Huo, Qiujin Shen & Wenxin Qin

Authors
  1. Xiufang Lv
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fengbo Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xisong Huo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Weidong Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Baoying Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiu Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Juan Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Qiujin Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Wenxin Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wenxin Qin.

Ethics declarations

Conflict of interest

No potential conflicts of interest were disclosed.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 346 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lv, X., Zhao, F., Huo, X. et al. Neuropeptide Y1 receptor inhibits cell growth through inactivating mitogen-activated protein kinase signal pathway in human hepatocellular carcinoma. Med Oncol 33, 70 (2016). https://doi.org/10.1007/s12032-016-0785-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-016-0785-1

Keywords

Search

Navigation